Skeletal muscle depletion predicts poor prognosis of patients with certain cancers. However, the correlation between low skeletal muscle index (SMI) and the prognosis of hepatocellular carcinoma (HCC) is not well understood. To determine their influence on prognosis, skeletal muscle index (SMI) and visceral fat area (VFA) were measured using computed tomography at the level of the third lumbar vertebra of 195 patients who underwent primary hepatectomy for hepatocellular carcinoma (HCC). We defined sarcopenia using cutoff values for SMI as 43.75 cm(2)/m(2) and 41.10 cm(2)/m(2) for males and females, respectively. Sarcopenia was present in 89 of 195 (45.6%) patients and correlated significantly (P < 0.001) with female sex, low body mass index (BMI), low subcutaneous fat area, low VFA, and low serum albumin levels. There was a trend indicating the association of sarcopenia with poor cumulative recurrence rate (CRR) (P = 0.13). In patients with BMI ≥22, CRR was significantly different between patients with or without sarcopenia (19.0 or 35.2 months, respectively, P = 0.03). In contrast, there was no significant difference in patients with BMI ≥22 as a function of VFA (P = 0.47). When the cohort was limited to patients with BMI ≥22, multivariate analysis showed that sarcopenia was a significant independent risk factor for recurrence (hazard ratio = 1.6; 95% confidence interval, 1.1-2.5; P = 0.02). Low-SMI was an independent adverse prognostic factor for CRR in patients with BMI ≥22. Therefore, preventing muscle wasting may improve the CRR of patients with HCC.
16 September 2015 in International Journal of Oncology
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
14 September 2013 in Journal of Experimental & Clinical Cancer Research
Background: To detect genes correlated with hepatocellular carcinoma (HCC), we developed a triple combination array consisting of methylation array, gene expression array and single nucleotide polymorphism (SNP) array analysis. Methods: A surgical specimen obtained from a 68-year-old female HCC patient was analyzed by triple combination array, which identified doublecortin domain-containing 2 (DCDC2) as a candidate tumor suppressor gene of HCC. Subsequently, samples from 48 HCC patients were evaluated for their DCDC2 methylation and expression status using methylation specific PCR (MSP) and semi-quantitative reverse transcriptase (RT) PCR, respectively. Then, we investigated the relationship between clinicopathological factors and methylation status of DCDC2. Results: DCDC2 was revealed to be hypermethylated (methylation value 0.846, range 0–1.0) in cancer tissue, compared with adjacent normal tissue (0.212) by methylation array in the 68-year-old female patient. Expression array showed decreased expression of DCDC2 in cancerous tissue. SNP array showed that the copy number of chromosome 6p22.1, in which DCDC2 resides, was normal. MSP revealed hypermethylation of the promoter region of DCDC2 in 41 of the tumor samples. DCDC2 expression was significantly decreased in the cases with methylation (P = 0.048). Furthermore, the methylated cases revealed worse prognosis for overall survival than unmethylated cases (P = 0.048). Conclusions: The present study indicates that triple combination array is an effective method to detect novel genes related to HCC. We propose that DCDC2 is a tumor suppressor gene of HCC.